WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 317322
CAS#: 42864-78-8 (HCl)
Description: Bevantolol Hydrochloride is a beta-1 adrenoceptor antagonist that has been shown to be as effective as other beta blockers for the treatment of angina pectoris and hypertension.
MedKoo Cat#: 317322
Name: Bevantolol Hydrochloride
CAS#: 42864-78-8 (HCl)
Chemical Formula: C20H28ClNO4
Exact Mass:
Molecular Weight: 381.89
Elemental Analysis: C, 62.90; H, 7.39; Cl, 9.28; N, 3.67; O, 16.76
Related CAS #: 59170-23-9 (free base) 42864-78-8 (HCl)
Synonym: Bevantolol Hydrochloride; Bevantolol HCl; Vantol; Cl 775; Cl775; Cl 775.
IUPAC/Chemical Name: 1-[2-(3,4-dimethoxyphenyl)ethylamino]-3-(3-methylphenoxy)propan-2-ol;hydrochloride
InChi Key: FJTKCFSPYUMXJB-UHFFFAOYSA-N
InChi Code: InChI=1S/C20H27NO4.ClH/c1-15-5-4-6-18(11-15)25-14-17(22)13-21-10-9-16-7-8-19(23-2)20(12-16)24-3;/h4-8,11-12,17,21-22H,9-10,13-14H2,1-3H3;1H
SMILES Code: OC(COC1=CC=CC(C)=C1)CNCCC2=CC=C(OC)C(OC)=C2.[H]Cl
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 381.89 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Noshiro T, Miura Y, Yoshinaga K, Iimura O, Inagaki Y, Saruta T, Ishii M,
Yamazaki N, Arakawa K. Clinical evaluation of bevantolol hydrochloride in
patients with severe hypertension. The Cooperative Study Group on Bevantolol in
Japan. Int J Clin Pharmacol Ther. 1995 Apr;33(4):240-5. PubMed PMID: 7620695.
2: Shiraishi K, Moriya M, Miyake N, Takayanagi I. Alpha 1-adrenoceptor blocking
activities of bevantolol hydrochloride(NC-1400) and labetalol in rat isolated
thoracic aorta--do they distinguish between subtypes? Gen Pharmacol. 1992
Sep;23(5):843-5. PubMed PMID: 1358746.
3: Takita M, Kigoshi S, Muramatsu I. Selectivity of bevantolol hydrochloride
towards alpha- and beta-adrenoceptor subtypes in rat cerebral cortex. Jpn J
Pharmacol. 1992 Feb;58(2):193-6. PubMed PMID: 1354761.
4: Kaplan HR. Pharmacology of bevantolol hydrochloride. Am J Cardiol. 1986 Nov
26;58(12):3E-7E. PubMed PMID: 2878599.
5: Kaplan HR. Bevantolol hydrochloride--preclinical pharmacologic profile.
Angiology. 1986 Mar;37(3 Pt 2):254-62. PubMed PMID: 2871786.
6: Löfdahl CG, Svedmyr K, Svedmyr N. Selectivity of bevantolol hydrochloride, a
beta 1-adrenoceptor antagonist, in asthmatic patients. Pharmacotherapy. 1984
Jul-Aug;4(4):205-10. PubMed PMID: 6148733.
